Peter Kalhs
Overview
Explore the profile of Peter Kalhs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
634
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oberbauer R, Edinger M, Berlakovich G, Kalhs P, Worel N, Heinze G, et al.
Front Med (Lausanne)
. 2021 Feb;
7:634260.
PMID: 33585521
The induction of donor-specific immunological tolerance could improve outcome after kidney transplantation. However, no tolerance protocol is available for routine clinical use. Chimerism-based regimens hold promise, but their widespread application...
2.
Harrison N, Grabmeier-Pfistershammer K, Graf A, Schwarzinger I, Aberle J, Stiasny K, et al.
NPJ Vaccines
. 2020 Sep;
5:79.
PMID: 32922963
[This corrects the article DOI: 10.1038/s41541-020-00215-1.].
3.
Harrison N, Grabmeier-Pfistershammer K, Graf A, Schwarzinger I, Aberle J, Stiasny K, et al.
NPJ Vaccines
. 2020 Jul;
5(1):67.
PMID: 32728481
The aim of this prospective study was to characterize the humoral immune response to TBE vaccination after hematopoietic stem cell transplantation (HSCT). Nineteen adult patients 11-13 months after HSCT and...
4.
Rodriguez-Arboli E, Labopin M, Tischer J, Brecht A, Ganser A, Finke J, et al.
Biol Blood Marrow Transplant
. 2020 Jul;
26(11):2165-2173.
PMID: 32717436
The use of myeloablative conditioning (MAC) in the setting of active relapsed/refractory (R/R) acute myeloid leukemia (AML) has been hindered by high historical rates of nonrelapse mortality (NRM). FLAMSA (fludarabine,...
5.
Anti-Apoptotic Molecule BCL2 Is a Therapeutic Target in Steroid-Refractory Graft-Versus-Host Disease
Strobl J, Pandey R, Krausgruber T, Kleissl L, Reininger B, Herac M, et al.
J Invest Dermatol
. 2020 Apr;
140(11):2188-2198.
PMID: 32247860
Graft-versus-host disease (GVHD) is the leading cause of mortality after hematopoietic stem cell transplantation and primarily affects barrier organs such as the skin. One-third of cases are refractory to steroid...
6.
Boban J, Kalhs P, Thurnher M
Acta Neurol Belg
. 2019 Aug;
120(5):1181-1183.
PMID: 31372840
No abstract available.
7.
Giebel S, Labopin M, Potter M, Poire X, Sengeloev H, Socie G, et al.
Eur J Cancer
. 2018 Apr;
96:73-81.
PMID: 29679774
Background: Allogeneic haematopoietic stem cell transplantation (alloHSCT) is considered a standard treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) achieving complete remission after induction containing tyrosine kinase...
8.
Worel N, Lehner E, Fuhrer H, Kalhs P, Rabitsch W, Mitterbauer M, et al.
Transfusion
. 2018 Feb;
58(4):1045-1053.
PMID: 29446444
Background: Extracorporeal photopheresis (ECP) has demonstrated efficacy as second-line treatment for steroid-refractory (SR) acute graft-versus-host disease (aGVHD). The aim of our study was to analyze whether the amount of ECP-treated...
9.
Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, et al.
J Hematol Oncol
. 2017 Jun;
10(1):130.
PMID: 28646908
Background: Primary refractory acute myeloid leukemia (PRF-AML) is associated with a dismal prognosis. Allogeneic stem cell transplantation (HSCT) in active disease is an alternative therapeutic strategy. The increased availability of...
10.
Worel N, Fritsch G, Agis H, Bohm A, Engelich G, Leitner G, et al.
J Clin Apher
. 2016 Sep;
32(4):224-234.
PMID: 27578390
Plerixafor in combination with granulocyte-colony stimulating factor (G-CSF) is approved for autologous stem cell mobilization in poor mobilizing patients with multiple myeloma or malignant lymphoma. The purpose of this study...